Relapsed or refractory #DLBCL remains difficult to treat after multiple therapies.
A phase 2 study found that dual #HDAC/PI3Kα inhibition with ifupinostat produced clinical responses, alongside substantial hematologic toxicity.
#STTT #OpenAccess: doi.org/10.1038/s413...
Relapsed or refractory #DLBCL remains difficult to treat after multiple therapies. A phase 2 study found that dual #HDAC/PI3Kα inhibition with ifupinostat produced clinical responses, alongside substantial hematologic toxicity. #STTT #OpenAccess: doi.org/10.1038/s413...
0 vue
Publié le 21/10/2026 12:45
0:24
Relapsed or refractory #DLBCL remains difficult to treat after multiple therapies.
A phase 2 study found that dual #HDAC/PI3Kα inhibition with ifupinostat produced clinical responses, alongside substantial hematologic toxicity.
#STTT #OpenAccess: doi.org/10.1038/s413...
0 commentaire
?